Medical news Today, Article Date: 03 Sep 2010
In a new peer-reviewed article published by the Journal of Translational Medicine, scientists from Beike Biotechnology, China's leading stem cell research and regenerative medicine company, and Medistem, Inc., reported positive safety data in 114 patients who were treated by doctors at Nanshan Affiliated Hospital of Guangdong Medical College (Shenzhen Nanshan Hospital) in Shenzhen using Beike's proprietary cord blood stem cell transplantation protocol. ...read more...
Original source: Safety evaluation of allogeneic umbilical cord blood mononuclear cell therapy for degenerative conditions
Journal of Translational Medicine 2010, 8:75doi:10.1186/1479-5876-8-75
Wan-Zhang Yang1 email, Yun Zhang2 email, Fang Wu1 email, Wei-Ping Min3 email, Boris Minev4 email, Min Zhang1 email, Xiao-Ling Luo2 email, Famela Ramos5 email, Thomas E Ichim5 email, Neil H Riordan5* email and Xiang Hu2*
Background
The current paradigm for cord blood transplantation is that HLA matching and immune suppression are strictly required to prevent graft versus host disease (GVHD). Immunological arguments and historical examples have been made that the use of cord blood for non-hematopoietic activities such as growth factor production, stimulation of angiogenesis, and immune modulation may not require matching or immune suppression.
Methods
114 patients suffering from non-hematopoietic degenerative conditions were treated with non-matched, allogeneic cord blood. Doses of 1-3 × 107 cord blood mononuclear cells per treatment, with 4-5 treatments both intrathecal and intravenously were performed. Adverse events and hematological, immunological, and biochemical parameters were analyzed for safety evaluation.
Results
No serious adverse effects were reported. Hematological, immunological, and biochemical parameters did not deviate from normal ranges as a result of therapy.
Conclusion
The current hematology-based paradigm of need for matching and immune suppression needs to be revisited when cord blood is used for non-hematopoietic regenerative purposes in immune competent recipients.
OPEN ACCES, GO TO FULL TEXT PDF
Friday, September 3, 2010
Subscribe to:
Posts (Atom)
